#United States #Miami #Resolve Therapeutics #RSLV-132 #RSLV-145

Resolve Therapeutics to Present at CNAPS

Resolve Therapeutics, a mid-stage clinical biopharmaceutical company focused on developing innovative non-immunosuppressive therapies for inflammatory diseases, has announced its participation in the upcoming International Symposium on Circulating Nucleic Acids in Plasma and Serum (CNAPS). The event will take place on December 4, 2025, in Hong Kong, where Dr. James Posada, the company's CEO, will deliver a presentation titled "Cell-free Nucleic Acids as Drug Targets in Autoimmunity and Acute Brain Injury."

In his remarks, Dr. Posada expressed enthusiasm about sharing the company's advancements in therapeutic development within the emerging field of cell-free nucleic acids. He noted that recent research has uncovered the significant role pathogenic nucleic acids play in driving inflammation, highlighting the potential for innovative treatments in areas with high unmet medical needs.

Understanding RSLV-132

One of the key products to be discussed is RSLV-132, a fully-human biologic drug designed to target and digest extracellular pathogenic cell-free RNA (cfRNA) linked to inflammatory processes. Unlike traditional immunosuppressive therapies that may compromise the immune system by depleting necessary B-cells or blocking vital cytokines, RSLV-132 specifically eliminates the inflammatory triggers without affecting overall immune function. With an extended serum half-life of three weeks and a documented excellent safety profile, RSLV-132 is currently being validated through clinical trials in conditions such as systemic lupus erythematosus (SLE) and Sjogren's disease, with a pivotal phase 2 trial ongoing in the latter group.

Innovative Approaches with RSLV-145

Additionally, Resolve Therapeutics is advancing RSLV-145, a dual-action drug that combines the capabilities of human DNase and RNase. This novel candidate aims to address both chronic and acute inflammatory diseases by digesting pathogenic nucleic acids responsible for triggering inflammation. Preclinical studies focus on subarachnoid hemorrhage where RSLV-145 has shown promise in reducing brain injury by eliminating cfRNA. Research is also ongoing in ischemic stroke, where the treatment's ability to break down neutrophil extracellular traps (NETs) could enhance the efficacy of existing therapies like tissue plasminogen activator (tPA).

The Future of Resolve Therapeutics

With its innovative approach to tackling diseases associated with circulating nucleic acids, Resolve Therapeutics is at the forefront of transforming how inflammatory diseases are treated. The company is poised to make a substantial impact in the biopharmaceutical landscape, offering hope through novel therapies that aim for effective disease management while preserving immune functionality.

As the symposium approaches, the scientific community eagerly anticipates the insights and developments that Resolve Therapeutics will unveil, potentially altering the future of treatment strategies in autoimmunity and acute brain injuries.

For more information about Resolve Therapeutics and its groundbreaking research, please visit resolvetherapeutics.com.